SOURCE: Novo Nordisk A/S

February 04, 2010 09:01 ET

Director/PDMR Shareholding

BAGSVAERD, DENMARK--(Marketwire - February 4, 2010) -


In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Please find below a statement of such trading in shares issued by Novo Nordisk.

+--------------------------------+--------------------------------+
|Name                            |Kurt Anker Nielsen              |
+--------------------------------+--------------------------------+
|Reason for reporting            |Member of the Board of Directors|
+--------------------------------+--------------------------------+
|Financial instrument and ID code|Novo Nordisk B DK006010261      |
+--------------------------------+--------------------------------+
|Type of transaction             |Sale of shares                  |
+--------------------------------+--------------------------------+
|Date of transaction             |3 February 2010                 |
+--------------------------------+--------------------------------+
|Place of transaction            |NASDAQ OMX Copenhagen           |
+--------------------------------+--------------------------------+
|Volume of transaction           |2,000 shares                    |
+--------------------------------+--------------------------------+
|Total value of transaction      |DKK 755,400                     |
+--------------------------------+--------------------------------+

Definitions and background information:

Publication

Publication shall take place the day after Novo Nordisk receives sufficient information on the trading. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)-3), or to which a board member/executive and/or a person mentioned in 1)-3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

Financial instrument includes shares listed on the NASDAQOMX Copenhagen and London Stock Exchange as well as ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX Copenhagen, the code (NVOB) on London Stock Exchange or the code (NVO) on New York Stock Exchange.

The volume of transaction is the number of shares (of DKK 1 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of shares traded on London Stock Exchange and ADRs listed on New York Stock Exchange.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs over 29,300 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

For further information please contact:


Media:                                  Investors:


Outside North America:                  Outside North America:
Mette Kruse Danielsen                   Klaus Bülow Davidsen
Tel: (+45) 4442 3883                    Tel: (+45) 4443 3176
E-mail:mkd@novonordisk.com              E-mail:klda@novonordisk.com
                                        Kasper Roseeuw Poulsen
                                        Tel: (+45) 4442 4471
                                        E-mail:krop@novonordisk.com



In North America:                       In North America
Sean Clements                           Hans Rommer
Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937
E-mail:secl@novonordisk.com             E-mail:hrmm@novonordisk.com

Company Announcement no 6 2010: http://hugin.info/2013/R/1380778/340236.pdf

Contact Information